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Resource utility {#s0005}
================

Genetic forms of FSGS with adult onset are extremely rare. Patients do not respond to available therapies and develop end stage renal failure. The generation of patient iPSCs offers a unique opportunity to elucidate FSGS pathogenic mechanism and to perform drug testing.

Resource details {#s0010}
================

Familial steroid-resistant nephrotic syndrome (SRNS) is a subgroup of idiopathic nephrotic syndrome classified by genetic mapping studies. Most identified mutations follow an autosomal recessive transmission and manifest early in life, while autosomal dominant forms usually present in late adolescence or adulthood. The most significant renal lesion of SRNS is Focal Segmental Glomerulosclerosis ([@bb0015]). Dysfunction of the glomerular podocyte, a specialized cell type that forms part of the glomerular filtration barrier, is pivotal for the pathogenesis of FSGS ([@bb0010]). The discovery of mutations in various genes encoding podocyte proteins is one of the most exciting advances in the understanding of FSGS pathogenesis. Mutations in PAX2 were previously associated with rare congenital abnormalities of the kidney and urinary tract, while little is known about the effects of PAX2 mutations in diseases affecting the glomerular components of the kidney. The PAX genes comprise a family of transcription factors that are active in different tissues during embryogenesis. In the developing kidney, PAX2 plays key roles in the differentiation and maturation of glomerular podocytes ([@bb0020]). In this study, we generated iPSCs from a patient carrying a recently identified disease-segregating missense heterozygous *PAX2* mutation (c.565G \> A). This mutation was associated with an adult onset autosomal dominant form of FSGS ([Table 1](#t0005){ref-type="table"}) ([@bb0005]). Human iPSCs were generated using the Sendai virus CytoTune reprogramming kit starting from PBMC, following the manufacturer\'s instructions. Twenty days after infection, around 30 colonies were picked and expanded singularly. Two isogenic clones described here, named IRFMNi002-A and IRFMNi002-B, were chosen for in-depth characterization. The Sendai virus genome and transgenes were completely absent after fourteen passages in culture ([Fig. 1](#f0005){ref-type="fig"}A, RT-PCR of PBMC 7 days after infection were used as the positive control). Sequencing of *PAX2* PCR product confirmed the presence of the heterozygous mutation c.565G \> A in the *PAX2* gene corresponding to a G189R mutation ([Fig. 1](#f0005){ref-type="fig"}B) in PAX2 protein. Human iPS cell lines showed all the properties typical of pluripotent stem cells in terms of pluripotency marker expression, as proven by immunostaining for OCT4, NANOG, TRA-1-60, TRA-1-81, SSEA-3 and SSEA-4 ([Fig. 1](#f0005){ref-type="fig"}C). Gene expression analysis confirmed the expression of pluripotency markers *OCT4*, *NANOG* and *SOX2* at comparable levels of human ESC H9, taken as the reference sample ([Fig. 1](#f0005){ref-type="fig"}D). Pluripotency properties were also supported by the ability to differentiate in vitro into derivatives of the three germ layers: mesoderm (α-SMA), ectoderm (β − III Tubulin) and endoderm (AFP) ([Fig. 1](#f0005){ref-type="fig"}E). Karyotype was routinely checked and the *c*ells showed a normal 46, XX karyotype ([Fig. 1](#f0005){ref-type="fig"}F). Finally, STR-PCR profile analysis was used to confirm cell identity between the parental PBMC and IRFMNi002-A, IRFMNi002-B clones ([Table 2](#t0010){ref-type="table"}, data not shown but available to the authors).Table 1Summary of lines.Table 1iPSC line namesAbbreviation in figuresGenderAgeEthnicityGenotype of locusDiseaseIRFMNi002-APRM\#14Female69CaucasianPAX2, c.565G \> AFocal Segmental GlomerulosclerosisIRFMNi002-BPRM\#18Female69CaucasianPAX2, c.565G \> AFocal Segmental GlomerulosclerosisFig. 1Characterization of IRFMNi002-A and IRFMNi002-B iPSC lines.Fig. 1Table 2Characterization and validation.Table 2ClassificationTestResultDataMorphologyPhotographyNormalNot shown but available with authorsPhenotypeQualitative analysis by ImmunocytochemistryAssess staining of pluripotency markers: OCT4, NANOG, TRA-1-60, TRA-1-81, SSEA-3, SSEA-4[Fig. 1](#f0005){ref-type="fig"} panel CQuantitative analysis by RT-qPCRAll the cell line express the pluripotency markers OCT4, NANOG and SOX2 at comparable level of H9 hES cells[Fig. 1](#f0005){ref-type="fig"} panel DGenotypeKaryotype (G-banding) and resolution46XX, Resolution 400[Fig. 1](#f0005){ref-type="fig"} panel FIdentityMicrosatellite PCR (mPCR) OR STR analysisNot performedN/A18 sites tested/MatchedSubmitted in archive with journalMutation analysis (IF APPLICABLE)SequencingHeterozygous c.565G \> A mutation[Fig. 1](#f0005){ref-type="fig"} panel BSouthern Blot OR WGSN/AN/AMicrobiology and virologyMycoplasmaMycoplasma testing by RT-PCR. Negative[Fig. 1](#f0005){ref-type="fig"}/SupplementaryDifferentiation potentialEmbryoid body formationMesoderm: smooth muscle actin[Fig. 1](#f0005){ref-type="fig"} panel EEctoderm: β-III-tubulinEndoderm α-feto proteinDonor screening (OPTIONAL)HIV 1 + 2 Hepatitis B, Hepatitis CN/AN/AGenotype additional info (OPTIONAL)Blood group genotypingN/AN/AHLA tissue typingN/AN/A

Materials and methods {#s0015}
=====================

Generation of human iPSCs {#s0020}
-------------------------

Human iPSCs were derived from peripheral blood mononuclear cells (PBMCs) through Sendai virus-mediated reprogramming using the CytoTune- iPS 2.0 Sendai reprogramming Kit (Life Technologies). PBMC were infected by hKOS, hc-Myc and hKLF4 Sendai virus and 3 days after infection were plated on MEF-feeder-coated dishes. Emergent colonies were manually picked about twenty days post-infection and cultured singly. After five passages, iPSCs were adapted to grow on hESC qualified- matrigel (BD Biosciences) in mTeSR1 medium and routinely subcultured using Accutase (Thermo Fisher Scientific). Cells were negative for mycoplasma contamination, detected using the N-GARDE Mycoplasma Detection PCR Kit (Euroclone) (Supplementary Fig. 1).

Sendai virus detection and pluripotency gene expression analysis {#s0025}
----------------------------------------------------------------

Total RNA was isolated with Trizol (Thermo Fisher Scientific) and treated with DNAse (Promega), as described by the manufacturer. Total RNA was used for reverse transcription reaction with the Vilo Superscript kit (Thermo Fisher Scientific). For Sendai virus detection, 10 μl of cDNA was submitted to PCR, using the primers listed in [Table 3](#t0015){ref-type="table"} and following the manufacturer\'s instructions. Samples were then separated on a 1.5% agarose gel. For pluripotency assessment, quantitative real- time PCR assays were performed using Taqman gene expression assays (Thermo Fisher Scientific), using predesigned Taqman probes for the genes of interest according to the supplier\'s recommendations ([Table 3](#t0015){ref-type="table"}).Table 3Reagents details.Table 3Antibodies used for immunocytochemistry/flow-citometryAntibodyDilutionCompany Cat \# and RRIDPluripotency markersMouse anti-OCT41:100Santa Cruz Biotechnology Cat\# sc-5279; RRID: [AB_628051](http://ab_628051){#ir0005}Rabbit anti-NANOG1:100Santa Cruz Biotechnology Cat\# sc-33759; RRID: [AB_2150401](http://ab_2150401){#ir0010}Mouse anti-TRA-1-601:200Millipore Cat\# MAB4360, RRID: [AB_2119183](nif-antibody:AB_2119183){#ir0015}Mouse anti-TRA-1-811:200Millipore Cat\# MAB4381, RRID: [AB_177638](nif-antibody:AB_177638){#ir0020}Mouse anti-SSEA-41:100Santa Cruz Biotechnology Cat\# sc-21704, RRID: [AB_628289](nif-antibody:AB_628289){#ir0025}Rat anti-SSEA-31:100Santa Cruz Biotechnology Cat\# sc-21703, RRID: [AB_628288](nif-antibody:AB_628288){#ir0030}Differentiation markersMouse anti-Tubulin beta-III, clone TU-20, Alexa Fluor 488 Conjugated1:100Millipore Cat\# CBL412X, RRID: [AB_1977541](nif-antibody:AB_1977541){#ir0035}Mouse anti-Actin, alpha-Smooth Muscle - Cy31:100Sigma-Aldrich Cat\# C6198, RRID: [AB_476856](nif-antibody:AB_476856){#ir0040}AFP (AFP-11) antibody1:100Santa Cruz Biotechnology Cat\# sc-51506, RRID: [AB_626514](nif-antibody:AB_626514){#ir0045}Secondary antibodiesDonkey anti-Rabbit IgG (H + L) Highly Cross-Adsorbed Secondary Antibody, Alexa Fluor 5461:300Thermo Fisher Scientific Cat\# A10040, RRID: [AB_2534016](nif-antibody:AB_2534016){#ir0050}Goat anti-Mouse IgM Heavy Chain Cross-Adsorbed Secondary Antibody, Alexa Fluor 4881:300Thermo Fisher Scientific Cat\# A-21042, RRID: [AB_2535711](nif-antibody:AB_2535711){#ir0055}Donkey anti-Mouse IgG (H + L) Highly Cross-Adsorbed Secondary Antibody, Alexa Fluor 5461:300Thermo Fisher Scientific Cat\# A10036, RRID: [AB_2534012](nif-antibody:AB_2534012){#ir0060}Alexa Fluor 488 goat anti-rat IgM (micro chain) ∗2 mg mL∗ antibody1:300Thermo Fisher Scientific Cat\# A-21212, RRID: [AB_2535798](nif-antibody:AB_2535798){#ir0065}  PrimersTargetForward/Reverse primer (5′-3′)SeV detection (RT-PCR)SeVForward: GGA TCA CTA GGT GAT ATC GAG CReverse: ACC AGA CAA GAG TTT AAG AGA TAT GTA TCKOSForward: ATG CAC CGC TAC GAC GTG AGC GCReverse: ACC TTG ACA ATC CTG ATG TGGKLF4Forward: TTC CTG CAT GCC AGA GGA GCC CReverse: AAT GTA TCG AAG GTG CTC AAc-MycForward: TAA CTG ACT AGC AGG CTT GTC GReverse: TCC ACA TAC AGT CCT GGA TGA TGA TGPluripotency Markers (qPCR)NANOGHs02387400_g1 (Thermo Fisher Scientific)OCT4Hs00742896_s1 (Thermo Fisher Scientific)SOX2Hs00602736_s1 (Thermo Fisher Scientific)House-Keeping Genes (qPCR)HPRT1Hs99999909_m1 (Thermo Fisher Scientific)GenotypingPAX2Forward: AGG GA TTG GAT GAG CTG TGCReverse: AC GGT TCT TGC TTC TCC TCCTargeted mutation sequencingPAX2Forward: AAA CTG GGC ACC ACT TAC CTReverse: CAC AGG GAT CGA TAG GGT GAG

Sequencing of mutation {#s0030}
----------------------

DNA was isolated with the DNeasy Blood & Tissue Kit (Qiagen). The *PAX2* gene was amplified by PCR using the primers listed in [Table 3](#t0015){ref-type="table"}. Sanger sequencing of PCR amplicon was carried out on 3730 DNA Analyzer (Applied Biosystem).

Immunocytochemistry {#s0035}
-------------------

The cells were fixed with PBS containing 4% paraformaldehyde for 15 min at room temperature (RT). After three washes with PBS, the cells were permeabilized with 0.3% Triton for 10 min at RT and then incubated for 1 h with 5% BSA as a blocking solution. The samples were stained with the primary antibody diluted in 2% BSA solution overnight at 4 °C, followed by incubation with the appropriate secondary antibody for 1 h at RT. Nuclei were counterstained with 4′,6-diamidino-2-phenylindole (DAPI) for 5 min at RT. Images were taken using the Axio Observer Z1 fluorescence microscope (Zeiss). The primary and secondary antibodies used are listed in [Table 3](#t0015){ref-type="table"}.

Embryoid body (EB) formation {#s0040}
----------------------------

For EB formation, human iPSCs were detached using dispase and transferred into Ultra Low-attach six well-plate (Corning) in DMEMF12 medium, supplemented with 20% KO serum, 0.1 mM 2-mercaptoethanol, 1× NEAA plus 10 μM rock inhibitor. Forty-eight hours after plating, rock inhibitor was removed and EBs were cultured for another 6 days as floating culture. Thereafter, EBs were transferred onto gelatin-coated plate for another 8 days.

Karyotyping {#s0045}
-----------

Metaphase spreads were prepared after 3 h of treatment with Colcemid (Roche) and processed for karyotype analysis. Karyotype analysis was performed in collaboration with the Genetic Medicine Laboratory of the Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII, Bergamo (Italy).

Cell line authentication {#s0050}
------------------------

Cell line authentication was performed by the ATCC Human STR Profiling Cell Authentication Service.

Appendix A. Supplementary data {#s0055}
==============================
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